Controls, Patients Post-COVID-19
Conditions
Keywords
SARS-CoV-2, Coronavirus, Sequelae, Exercise intolerance, Cardiopulmonary exercise testing
Brief summary
The project is designed as a cross-sectional study and aims to examine long-term consequences of coronavirus disease 2019 (COVID-19) for selected bio-behavioural parameters while taking the disease course severity into account.
Interventions
DIAGNOSTIC_TESTCardiorespiratory fitness
Cardiopulmonary exercise testing
DIAGNOSTIC_TESTLung function
Body plethysmography
DIAGNOSTIC_TESTMuscular strength and balance tests
Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance
DIAGNOSTIC_TESTMicro- and macrovascular endothelial function and cardiac function
Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography
DIAGNOSTIC_TESTBlood sampling and analysis
Blood sampling by venepuncture
DIAGNOSTIC_TESTPhysical activity
Physical activity surveillance using accelerometers
DIAGNOSTIC_TESTQuestionnaires
Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms
DIAGNOSTIC_TESTBody composition
Dual-energy x-ray absorptiometry (DXA)
Sponsors
Arno Schmidt-Trucksäss
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* tested positive for SARS-CoV-2 using antigen- or PCR tests within the last 18 months * previous hospitalisation due to COVID-19 * fully vaccinated (only for controls)
Exclusion criteria
* inability to follow the study procedures (e.g. due to language barriers, psychological disorders, dementia, etc.), * known pregnancy or lactating women, * presence of any contraindications for exercising until maximum exhaustion, including insufficient blood pressure control (systolic \>170 mmHg, diastolic \>100 mmHg), ongoing cancer treatment, unstable angina pectoris, uncontrolled bradyarrhythmia or tachyarrhythmia, severe uncorrected valvular heart disease, clinically relevant acute infection, any form of musculoskeletal injury, * participating in any interventional clinical trial within the last four weeks, * previous participation in the current study * history of symptomatic COVID-19 (only for controls)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cardiorespiratory fitness (as % of predicted V̇O2max) | 1.5 hours after inclusion in study | Measured during cardiopulmonary exercise testing on a cycle ergometer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Forced vital capacity (as % of predicted) | 1.5 hours after inclusion in study | Measured during bodyplethysmography. |
| Total lung capacity (as % of predicted) | 1.5 hours after inclusion in study | Measured during bodyplethysmography. |
| Diffusion capacity of the lungs (as % of predicted) | 1.5 hours after inclusion in study | Measured during bodyplethysmography. |
| Muscle oxygenation at peak exercise (in %) | 1.5 hours after inclusion in study | Measured using near-infrared spectroscopy during cardiopulmonary exercise testing on a cycle ergometer. |
| Cardiac output at peak exercise (in mL) | 1.5 hours after inclusion in study | Measured non-invasive using the PhysioFlow device during cardiopulmonary exercise testing on a cycle ergometer. |
| Handgrip strength (in N) | 1 hour after inclusion in study | Measured by a handheld dynamometer. |
| Forced expiratory volume in 1 s (as % of predicted) | 1.5 hours after inclusion in study | Measured during bodyplethysmography. |
| Macrovascular flow-mediated dilation at rest (in %) | 0.5 hours after inclusion in study | Measured by ultrasound. |
| Microvascular flow-mediated dilation at rest (in %) | 2 to 14 days after inclusion in study | Measured by retinal vessel analysis. |
| Fatigue Assessment Scale (FAS) score | 2 to 14 days after inclusion in study | Scores range from 5 to 50 with higher scores indicating more severe fatigue. |
| Score of depression, anxiety, and stress questionnaire (DASS21) | 2 to 14 days after inclusion in study | Scores range from 0 to 63 with higher scores indicating worse mental health. |
| Health distance | Calculated during statistical analysis | The statistical (Mahalanobis) distance (health distance) is a composite measure of various health biomarkers |
| Cerebral oxygenation at peak exercise (in %) | 1.5 hours after inclusion in study | Measured using functional near-infrared spectroscopy during cardiopulmonary exercise testing on a cycle ergometer. |
| Handgrip rate of force development (in N/s) | 1 hour after inclusion in study | Measured by a handheld dynamometer. |
Countries
Switzerland
Contacts
Primary ContactArno Schmidt-Trucksäss, Prof.
Outcome results
None listed